Strong Overseas Sales of COVID-19 Vaccines: Moderna (MRNA.US) Turns a Profit in Q3 and Significantly Raises Full-Year Revenue Guidance

智通财经2026/11/06 12:21

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jin Zhitong Finance APP has learned that before the U.S. stock market opened on November 6, Moderna (MRNA.US) announced its third-quarter 2026 results. The financial report shows that the company's total revenue was $1.313 billion, a year-on-year increase of 29%, far exceeding market expectations of about $885 million; net profit was $162 million, reversing last year's net loss of $200 million; diluted earnings per share were $0.38, significantly better than the market expectation of a loss of $1.25 per share.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Strong Overseas Sales of COVID-19 Vaccines: Moderna (MRNA.US) Turns a Profit in Q3 and Significantly Raises Full-Year Revenue Guidance

You may also like

Crypto prices